711
Views
14
CrossRef citations to date
0
Altmetric
Articles

The Europeanization of Health Care Coverage Decisions: EU-Regulation, Policy Learning and Cooperation in Decision-Making

&

References

  • Arrow, K.J. 1963. Uncertainty and the welfare economics of medical care. American Economic Review 53, no.5: 941–73.
  • Banta, D., Kristensen F.B., & Jonsson E. 2009. A history of health technology assessment at the European level. International Journal of Technology Assessment in Health Care 25, S1: 68–73.
  • Banta, D., and W. Oortwijn. 2000. Health technology assessment in the European Union. International Journal of Technology Assessment in Health Care 16, no. 2: 299–635.
  • Böhm, K., Landwehr, C. and Steiner, N. 2013. What explains ‘generosity’ in the public financing of high-tech drugs? An empirical investigation for 25 OECD countries and 11 controversial drugs. Journal of European Social Policy, forthcoming.
  • Busse, R., E. van Ginneken, J. Schreyögg, and M. Velasco Garrido. 2011. Benefit Baskets and Tariffs. In Cross-Border Health Care in the European Union. Mapping and Analysing Practices and Policies, eds. Wismar, M., W. Palm, J. Figueras, K. Ernst, and E. van Ginneken, 91–120. Copenhagen: WHO Regional Office for Europe.
  • Drummond, M. 1987. Economic appraisal of health technology in the European Community. Oxford: Oxford University Press.
  • ECHTA/ECAHI. 2001. The ECHTA/ECAHI project, report, http://ec.europa.eu/health/ph_projects/1999/monitoring/fp_monitoring_1999_frep_09_en.pdf (accessed 15 July 2011).
  • EUnetHTA. 2009. EUnetHTA project. Overview of results. Years 2006-2008, http://www.eunethta.eu/upload/Project%20Reporting/EUnetHTA%20project_Overview%20of%20Results_2006-2008.pdf (accessed 18 July 2011).
  • European Commission. 2008a. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions safe, innovative and accessible medicines: a renewed vision for the pharmaceutical sector. COM (2008) 666, available at http://ec.europa.eu/health/human-use/package_en.htm (accessed 8 July 2011).
  • European Commission. 2008b. Communication from the Commission: a community framework on the application of patients' rights in cross-border healthcare. COM (2008) 415, available at http://ec.europa.eu/health-eu/doc/com2008415_en.pdf (accessed 8 July 2011).
  • European Commission. 2010. Review of Council Directive 89/105/EEC relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems, roadmap, available at http://ec.europa.eu/governance/impact/planned_ia/roadmaps_2011_en.htm#enterprise (6 July 2011).
  • European Parliament, and European Council. 2011. Directive of the European Parliament and of the Council on the application of patients' rights in cross-border healthcare, Directive 2011/24/EU, available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF (accessed 8 July 2011.
  • Featherstone, K. 2003. Introduction: in the name of ‘Europe’. In The politics of Europeanization, eds. K. Featherstone and C. Radaelli, 3–26. Oxford: Oxford University Press.
  • Federal Joint Committee. 2013. Versorgung mit innovativen Arzneimitteln in Deutschland auf hohem Niveau: Internationaler Vergleich belegt bei früher Nutzenbewertung positive Tendenz, press release 7 February 2013, available at http://www.g-ba.de/institution/presse/pressemitteilungen/473/ (accessed 22 February 22, 2012).
  • Folland, S., A.C. Goodman, and M. Stano. 2010. The Economics of health and health care, 6th edn. Boston: Prentice Hall.
  • Fracchia, G.N., and M. Theofilatou. 1993. Health Services Research. Washington, DC: IOS Press.
  • Martinsen, D.S. 2012. The Europeanization of Health Care. In Research design in European studies: establishing causality in Europeanization, eds. T. Exadaktylos and C. Radaelli, 141–59. Basingstoke: Palgrave Macmillan.
  • Mrazek, M.F., and E. Mossialos. 2004. Regulating pharmaceutical prices in the European Union. In Regulating pharmaceuticals in Europe: Striving for efficiency, equity and quality, 114–29, eds. E. Mossialos, M.F. Mrazek and T. Walley. Maidenhead: Open University Press.
  • Niżankowski, R. and Wilk, N. 2009. From idealistic rookies to a regional leader: the history of health technology assessment in Poland. International Journal of Technology Assessment in Health Care 25 (S1): 156.
  • OECD (2010) Health at a glance: Europe 2010 (OECD).
  • Permanand, G. 2006. EU pharmaceutical regulation: the politics of policy-making. Manchester: Manchester University Press.
  • Radaelli, C. 2003. The Europeanization of public policy. In The politics of Europeanization, eds. Kevin Featherstone and Claudio Radaelli, 27–56. Oxford: Oxford University Press.
  • Radaelli, C., and R. Pasquier. 2008. Conceptual issues. In Europeanization, eds. Paolo Graziano and Marteen P. Vink, 35–45. Basingstoke: Palgrave Macmillan.
  • Røttingen, J., A. Gerhardus, and M. Velasco Garrido. 2008. Future challenges for HTA in Europe. In Health Technology Assessment and health policy-making in Europe: current status, challenges and potential, eds. F.B. Kristensen, M. Velasco Garrido, C.P. Nielsen and R. Busse, 161–81. Copenhagen: WHO Regional Office for Europe.
  • Velasco Garrido, M., J. Schreyögg, T. Stargardt, and R. Busse. 2006. Identification of health baskets in nine EU Countries. Revue Française des Affaires sociales 6: 63–88.
  • Velasco Garrido, M., A. Zentner, and R. Busse. 2008. Health systems, health policy and health technology assessment. In Health Technology Assessment and health policy-making in Europe: current status, challenges and potential, eds. F.B. Kristensen, M. Velasco Garrido, C.P. Nielsen and R. Busse, 53–78. Copenhagen: WHO Regional Office for Europe.
  • Vink, M.P., and P. Graziano. 2008. Challenges of a new research agenda. In Europeanization: new research agendas, eds. P. Graziano and M.P. Vink, 3–20. Basingstoke: Palgrave Macmillan.
  • Vogler, S., J. Espin, and C. Habl. 2009. Pharmaceutical Pricing and Reimbursement Information (PPRI): new PPRI analysis including Spain. Pharmaceuticals Policy and Law 11: 231–234.
  • Zagorska, A., Z. Krol, I. Lipska, A. Falek, P. Sauvage, A. Barna, and T. van Ormondt. 2008. Implementation of transparent process of drug reimbursement decisions in Poland. Value in Health 11, no. 6: A348–A349.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.